Immix Biopharma (IMMX) Share-based Compensation (2021 - 2026)

Immix Biopharma (IMMX) has 6 years of Share-based Compensation data on file, last reported at $508065.0 in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 16.88% year-over-year to $508065.0; the trailing twelve-month figure through Mar 2026 stood at $3.5 million (up 83.59% YoY), and the FY2025 full-year result was $2.4 million, down 19.16% from the prior year.
• Share-based Compensation slipped to $508065.0 in Q1 2026, from $2.4 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $2.4 million in Q4 2025 to a low of $65074.0 in Q1 2022.
• A 5-year average of $552653.4 and a median of $441178.5 in 2023 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation surged 1432.23% in 2022 and sank 74.46% in 2025, its largest moves.
• Tracing IMMX's Share-based Compensation over 5 years: stood at $130094.0 in 2022, then soared by 707.73% to $1.1 million in 2023, then slumped by 32.85% to $705653.0 in 2024, then soared by 246.04% to $2.4 million in 2025, then slumped by 79.19% to $508065.0 in 2026.
• Business Quant data shows IMMX's Share-based Compensation at $508065.0 in Q1 2026, $2.4 million in Q4 2025, and $75046.0 in Q2 2025.